Market Cap 20.25B
Revenue (ttm) 9.68B
Net Income (ttm) 1.63B
EPS (ttm) N/A
PE Ratio 8.52
Forward PE 8.89
Profit Margin 16.87%
Debt to Equity Ratio 0.27
Volume 1,865,300
Avg Vol 1,622,348
Day's Range N/A - N/A
Shares Out 146.38M
Stochastic %K 2%
Beta 0.01
Analysts Sell
Price Target $196.00

Latest News on BIIB

Biogen Analysts Lower Their Forecasts After Q4 Results

Feb 13, 2025, 9:03 AM EST - 6 weeks ago

Biogen Analysts Lower Their Forecasts After Q4 Results


Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 12:41 PM EST - 6 weeks ago

Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript


Drugmaker Biogen forecasts 2025 profit below expectations

Feb 12, 2025, 6:47 AM EST - 6 weeks ago

Drugmaker Biogen forecasts 2025 profit below expectations


Europe to review safety data for Eisai-Biogen Alzheimer's drug

Jan 31, 2025, 6:46 AM EST - 2 months ago

Europe to review safety data for Eisai-Biogen Alzheimer's drug


Sage rejects Biogen's $469 million takeover offer

Jan 27, 2025, 9:28 AM EST - 2 months ago

Sage rejects Biogen's $469 million takeover offer


Biogen CEO sees no burning need for more acquisitions

Jan 14, 2025, 6:01 PM EST - 2 months ago

Biogen CEO sees no burning need for more acquisitions


Beaten Down Biogen Stock Looks Attractive At Current Levels

Dec 30, 2024, 1:37 PM EST - 3 months ago

Beaten Down Biogen Stock Looks Attractive At Current Levels


5 Healthcare Stocks to Buy in a Beaten-Up Sector

Nov 14, 2024, 1:53 PM EST - 4 months ago

5 Healthcare Stocks to Buy in a Beaten-Up Sector

AMGN LLY PFE XLV


EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen

Nov 14, 2024, 11:17 AM EST - 4 months ago

EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen


Biogen Analysts Slash Their Forecasts After Q3 Results

Oct 31, 2024, 1:28 PM EDT - 5 months ago

Biogen Analysts Slash Their Forecasts After Q3 Results